Abstract

Background

Recently, antimigraine drugs targeting the calcitonin gene-related peptide pathway have been approved for clinical use as preventive migraine medication.

Case report

We present a case of a 54-year-old male migraine patient, who reported erectile dysfunction as a possible side effect of treatment with galcanezumab, a monoclonal antibody targeting calcitonin gene-related peptide. His potency recovered after treatment discontinuation.

Discussion

As calcitonin gene-related peptide is involved in mammalian penile erection, erectile dysfunction is a conceivable side effect associated with calcitonin gene-related peptide inhibition. Postmarketing surveillance will elucidate the actual incidence of erectile dysfunction in patients using these new antimigraine drugs, and determine whether a causal relationship between calcitonin gene-related peptide inhibition and erectile dysfunction exists. This would be relevant not only because of the direct sexual consequences of erectile dysfunction, but also considering the potential cardiovascular consequences of calcitonin gene-related peptide (receptor) blockade and the association of both migraine and erectile dysfunction with cardiovascular disease.

Conclusion

Erectile dysfunction might be an overlooked, but reversible side effect in male migraine patients using monoclonal antibodies that inhibit the calcitonin gene-related peptide pathway, including galcanezumab. This paper may raise clinical awareness and suggest that this potential side effect needs to be studied further.

中文翻译：

---

勃起功能障碍可能是 CGRP 抑制的副作用吗？案例报告

摘要

背景

最近，针对降钙素基因相关肽通路的抗偏头痛药物已被批准用于临床作为预防偏头痛的药物。

案例报告

我们介绍了一个 54 岁男性偏头痛患者的案例，他报告了勃起功能障碍可能是使用 galcanezumab（一种靶向降钙素基因相关肽的单克隆抗体）治疗的副作用。他的效力在治疗中断后恢复。

讨论

由于降钙素基因相关肽参与哺乳动物阴茎勃起，勃起功能障碍是与降钙素基因相关肽抑制相关的可想象的副作用。上市后监测将阐明使用这些新型抗偏头痛药物的患者勃起功能障碍的实际发生率，并确定降钙素基因相关肽抑制与勃起功能障碍之间是否存在因果关系。这不仅是因为勃起功能障碍的直接性后果，而且还考虑到降钙素基因相关肽（受体）阻断的潜在心血管后果以及偏头痛和勃起功能障碍与心血管疾病的关联。

结论

对于使用抑制降钙素基因相关肽途径的单克隆抗体（包括 galcanezumab）的男性偏头痛患者，勃起功能障碍可能是一种被忽视但可逆的副作用。本文可能会提高临床意识，并表明需要进一步研究这种潜在的副作用。